|
1
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 4
17 Suppl:iv1–iv62. 2015. View Article : Google Scholar
|
|
2
|
Wang X, Chen JX, Zhou Q, Liu YH, Mao Q,
You C, Chen N, Xiong L, Duan J and Liu L: Statistical report of
central nervous system tumors histologically diagnosed in the
Sichuan province of China from 2008 to 2013: A West China Glioma
Center report. Ann Surg Oncol. 23 Suppl 5:S946–S953. 2016.
View Article : Google Scholar
|
|
3
|
Lim B, Allen JE, Prabhu VV, Talekar MK,
Finnberg NK and El-Deiry WS: Targeting TRAIL in the treatment of
cancer: New developments. Expert Opin Ther Targets. 19:1171–1185.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kichev A, Rousset CI, Baburamani AA,
Levison SW, Wood TL, Gressens P, Thornton C and Hagberg H: Tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling
and cell death in the immature central nervous system after
hypoxia-ischemia and inflammation. J Biol Chem. 289:9430–9439.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bo Y, Guo G and Yao W: MiRNA-mediated
tumor specific delivery of TRAIL reduced glioma growth. J
Neurooncol. 112:27–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Förster A, Falcone FH, Gibbs BF, Preussner
LM, Fiebig BS, Altunok H, Seeger JM, Cerny-Reiterer S, Rabenhorst
A, Papenfuss K, et al: Anti-Fas/CD95 and tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) differentially
regulate apoptosis in normal and neoplastic human basophils. Leuk
Lymphoma. 54:835–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J,
Chen J, Wen Z and Jiang X: TRAIL and doxorubicin combination
enhances anti-glioblastoma effect based on passive tumor targeting
of liposomes. J Control Release. 154:93–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao JQ, Lv Q, Li LM, Tang XJ, Li FZ, Hu YL
and Han M: Glioma targeting and blood-brain barrier penetration by
dual-targeting doxorubincin liposomes. Biomaterials. 34:5628–5639.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Holoch PA and Griffith TS: TNF-related
apoptosis-inducing ligand (TRAIL): A new path to anti-cancer
therapies. Eur J Pharmacol. 625:63–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kelley SK and Ashkenazi A: Targeting death
receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol.
4:333–339. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bagci-Onder T, Agarwal A, Flusberg D,
Wanningen S, Sorger P and Shah K: Real-time imaging of the dynamics
of death receptors and therapeutics that overcome TRAIL resistance
in tumors. Oncogene. 32:2818–2827. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perlstein B, Finniss SA, Miller C,
Okhrimenko H, Kazimirsky G, Cazacu S, Lee HK, Lemke N, Brodie S,
Umansky F, et al: TRAIL conjugated to nanoparticles exhibits
increased anti-tumor activities in glioma cells and glioma stem
cells in vitro and in vivo. Neuro Oncol. 15:29–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Redjal N, Zhu Y and Shah K: Combination of
systemic chemotherapy with local stem cell delivered S-TRAIL in
resected brain tumors. Stem Cells. 33:101–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Balyasnikova IV, Prasol MS, Ferguson SD,
Han Y, Ahmed AU, Gutova M, Tobias AL, Mustafi D, Rincón E, Zhang L,
et al: Intranasal delivery of mesenchymal stem cells significantly
extends survival of irradiated mice with experimental brain tumors.
Mol Ther. 22:140–148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi SA, Yun JW, Joo KM, Lee JY, Kwak PA,
Lee YE, You JR, Kwon E, Kim WH, Wang KC, et al: Preclinical
biosafety evaluation of genetically modified human adipose
tissue-derived mesenchymal stem cells for clinical applications to
brainstem glioma. Stem Cells Dev. 25:897–908. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Asahara T and Kawamoto A: Endothelial
progenitor cells for postnatal vasculogenesis. Am J Physiol Cell
Physiol. 287:C572–C579. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Asahara T, Murohara T, Sullivan A, Silver
M, van der Zee R, Li T, Witzenbichler B, Schatteman G and Isner JM:
Isolation of putative progenitor endothelial cells for
angiogenesis. Science. 275:964–967. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fang J, Chen X, Wang S, Xie T, Du X, Liu
H, Wang S, Li X, Chen J, Zhang B, et al: The expression of
P2X7 receptors in EPCs and their potential role in the
targeting of EPCs to brain gliomas. Cancer Biol Ther. 16:498–510.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Varma NR, Shankar A, Iskander A, Janic B,
Borin TF, Ali MM and Arbab AS: Differential biodistribution of
intravenously administered endothelial progenitor and cytotoxic
T-cells in rat bearing orthotopic human glioma. BMC Med Imaging.
13:172013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Flamini V, Jiang WG, Lane J and Cui YX:
Significance and therapeutic implications of endothelial progenitor
cells in angiogenic-mediated tumour metastasis. Crit Rev Oncol
Hematol. 100:177–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marçola M and Rodrigues CE: Endothelial
progenitor cells in tumor angiogenesis: Another brick in the wall.
Stem Cells Int. 2015:8326492015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de la Puente P, Muz B, Azab F and Azab AK:
Cell trafficking of endothelial progenitor cells in tumor
progression. Clin Cancer Res. 19:3360–3368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang L, Chen L, Wang Q, Wang L, Wang H,
Shen Y, Li X, Fu Y, Shen Y and Yu Y: Circulating endothelial
progenitor cells are involved in VEGFR-2-related endothelial
differentiation in glioma. Oncol Rep. 32:2007–2014. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang SH, Xiang P, Wang HY, Lu YY, Luo YL
and Jiang H: The characteristics of bone marrow-derived endothelial
progenitor cells and their effect on glioma. Cancer Cell Int.
12:322012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kang SD, Carlon TA, Jantzen AE, Lin FH,
Ley MM, Allen JD, Stabler TV, Haley NR, Truskey GA and Achneck HE:
Isolation of functional human endothelial cells from small volumes
of umbilical cord blood. Ann Biomed Eng. 41:2181–2192. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao W, Waggoner J, Zhang ZG, Lam CK, Han
P, Qian J, Schroder PM, Mitton B, Kontrogianni-Konstantopoulos A,
Robia SL and Kranias EG: The anti-apoptotic protein HAX-1 is a
regulator of cardiac function. Proc Natl Acad Sci USA. 106:pp.
20776–20781. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang G, Tao L, Shen S and Chen L: Hypoxia
induced CCL28 promotes angiogenesis in lung adenocarcinoma by
targeting CCR3 on endothelial cells. Sci Rep. 6:271522016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peichev M, Naiyer AJ, Pereira D, Zhu Z,
Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA and Rafii
S: Expression of VEGFR-2 and AC133 by circulating human CD34(+)
cells identifies a population of functional endothelial precursors.
Blood. 95:952–958. 2000.PubMed/NCBI
|
|
29
|
Fadini GP, Losordo D and Dimmeler S:
Critical reevaluation of endothelial progenitor cell phenotypes for
therapeutic and diagnostic use. Circ Res. 110:624–637. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Laurenzana A, Biagioni A, D'Alessio S,
Bianchini F, Chillà A, Margheri F, Luciani C, Mazzanti B,
Pimpinelli N, Torre E, et al: Melanoma cell therapy: Endothelial
progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme.
Oncotarget. 5:3711–3727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Purwanti YI, Chen C, Lam DH, Wu C, Zeng J,
Fan W and Wang S: Antitumor effects of CD40 ligand-expressing
endothelial progenitor cells derived from human induced pluripotent
stem cells in a metastatic breast cancer model. Stem Cells Transl
Med. 3:923–935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de Miguel D, Lemke J, Anel A, Walczak H
and Martinez-Lostao L: Onto better TRAILs for cancer treatment.
Cell Death Differ. 23:733–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ozören N and El-Deiry WS: Defining
characteristics of Types I and II apoptotic cells in response to
TRAIL. Neoplasia. 4:551–557. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rudner J, Jendrossek V, Lauber K, Daniel
PT, Wesselborg S and Belka C: Type I and type II reactions in
TRAIL-induced apoptosis-results from dose-response studies.
Oncogene. 24:130–140. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rozanov DV, Savinov AY, Golubkov VS,
Rozanova OL, Postnova TI, Sergienko EA, Vasile S, Aleshin AE, Rega
MF, Pellecchia M and Strongin AY: Engineering a leucine
zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells.
Mol Cancer Ther. 8:1515–1525. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Berg D, Lehne M, Müller N, Siegmund D,
Münkel S, Sebald W, Pfizenmaier K and Wajant H: Enforced covalent
trimerization increases the activity of the TNF ligand family
members TRAIL and CD95L. Cell Death Differ. 14:2021–2034. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schneider B, Münkel S,
Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, Pfizenmaier
K and Gerspach J: Potent antitumoral activity of TRAIL through
generation of tumor-targeted single-chain fusion proteins. Cell
Death Dis. 1:e682010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Siegemund M, Pollak N, Seifert O, Wahl K,
Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, et al:
Superior antitumoral activity of dimerized targeted single-chain
TRAIL fusion proteins under retention of tumor selectivity. Cell
Death Dis. 3:e2952012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mitchell MJ, Wayne E, Rana K, Schaffer CB
and King MR: TRAIL-coated leukocytes that kill cancer cells in the
circulation. Proc Natl Acad Sci USA. 111:pp. 930–935. 2014;
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Loi M, Becherini P, Emionite L, Giacomini
A, Cossu I, Destefanis E, Brignole C, Di Paolo D, Piaggio F, Perri
P, et al: sTRAIL coupled to liposomes improves its pharmacokinetic
profile and overcomes neuroblastoma tumour resistance in
combination with Bortezomib. J Control Release. 192:157–166. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yan C, Li S, Li Z, Peng H, Yuan X, Jiang
L, Zhang Y, Fan D, Hu X, Yang M and Xiong D: Human umbilical cord
mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion
protein delivery: A double-target therapy against non-Hodgkin's
lymphoma. Mol Pharm. 10:142–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Seifert O, Pollak N, Nusser A, Steiniger
F, Rüger R, Pfizenmaier K and Kontermann RE: Immuno-LipoTRAIL:
Targeted delivery of TRAIL-functionalized liposomal nanoparticles.
Bioconjug Chem. 25:879–887. 2014. View Article : Google Scholar : PubMed/NCBI
|
